title: Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121.
abstract: BACKGROUND
  The application is in the field of medication and treatment for MS.
  
  
  OBJECTIVE
  It aims at identifying and characterizing the activity and potency of antibodies against CD20 (rituximab) for treating MS and at devising treatments and dosing protocols for various forms of MS.
  
  
  METHODS
  Various doses of antibody and different time points were assessed to devise treatments and dosing protocols for MS.
  
  
  RESULTS
  Rituximab depletes peripheral B cells and reduces the level of B cells in the cerebrospinal fluid of patients with relapsing-remitting MS. Various treatments and dosing protocols are proposed for improving the signs, symptoms or other indicators of patients with relapsing-remitting MS and with primary progressive MS.
  
  
  CONCLUSIONS
  Antibodies against CD20 and rituximab offer new opportunities to treat patients with MS. The application claims the use of antibodies against CD20 and rituximab for treating the various forms of MS. The application claims the administration of the antibodies at separate intervals, and alone or in combination with other drugs and treatments. It claims a manufacture product for the medication. It further claims the administration of antibodies against CD20 by gene therapy for treating MS.
authors.affiliation: Dublin City University, School of Biotechnology, Glasnevin, Dublin 9, Ireland. philippe.taupin@dcu.ie
authors.forename: Philippe
authors.initials: P
authors.lastname: Taupin
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D018951:Antigens, CD20 / Q000276:immunology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy / Q000276:immunology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy / Q000276:immunology; D010330:Patents as Topic; D000069283:Rituximab; D013997:Time Factors
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D007155:Immunologic Factors; D000069283:Rituximab